A Post Marketing Surveillance Study to Monitor the Reactogenicity and Safety of Vaxem Hib When Administered According to the Prescribing Information in Korea
Phase of Trial: Phase IV
Latest Information Update: 10 Sep 2012
At a glance
- Drugs TAK 816 (Primary)
- Indications Haemophilus infections
- Focus Adverse reactions
- Sponsors Novartis; Novartis Vaccines
- 10 Sep 2012 Actual patient number changed from 759 to 764, as reported by ClinicalTrials.gov.
- 10 Sep 2012 Actual end date (Jul 2012) added as reported by ClinicalTrials.gov.
- 01 Jul 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.